MX2024009165A - Proteinas de fusion de ligador triespecifico del linfocito t inmunomodulador - Google Patents
Proteinas de fusion de ligador triespecifico del linfocito t inmunomoduladorInfo
- Publication number
- MX2024009165A MX2024009165A MX2024009165A MX2024009165A MX2024009165A MX 2024009165 A MX2024009165 A MX 2024009165A MX 2024009165 A MX2024009165 A MX 2024009165A MX 2024009165 A MX2024009165 A MX 2024009165A MX 2024009165 A MX2024009165 A MX 2024009165A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion proteins
- cell
- trispecific
- immunomodulatory
- linker fusion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263303481P | 2022-01-26 | 2022-01-26 | |
| US202263417655P | 2022-10-19 | 2022-10-19 | |
| PCT/CA2023/050103 WO2023141713A1 (en) | 2022-01-26 | 2023-01-26 | Immunomodulatory trispecific t cell engager fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009165A true MX2024009165A (es) | 2024-12-06 |
Family
ID=87469895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009165A MX2024009165A (es) | 2022-01-26 | 2024-07-24 | Proteinas de fusion de ligador triespecifico del linfocito t inmunomodulador |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250019440A1 (https=) |
| EP (1) | EP4469488A4 (https=) |
| JP (1) | JP2025504909A (https=) |
| KR (1) | KR20240137058A (https=) |
| AU (1) | AU2023212483A1 (https=) |
| CA (1) | CA3247443A1 (https=) |
| IL (1) | IL314169A (https=) |
| MX (1) | MX2024009165A (https=) |
| WO (1) | WO2023141713A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023312397A1 (en) * | 2022-07-29 | 2025-03-13 | Zymeworks Bc Inc. | Multivalent and bispecific antibody constructs and methods of use thereof |
| CA3266966A1 (en) * | 2022-10-19 | 2024-04-25 | Zymeworks Bc Inc. | TRIVALENT AND TRISPECIFIC ANTIBODY CONSTRUCTIONS AND THEIR METHODS OF USE |
| WO2025085862A2 (en) * | 2023-10-20 | 2025-04-24 | BioNTech SE | Multispecific t cell engagers compositions and methods of use thereof |
| WO2025122988A2 (en) * | 2023-12-08 | 2025-06-12 | Aarvik Therapeutics, Inc. | Engineered antibodies and immunoconjugates and methods of use |
| TW202600597A (zh) * | 2024-03-04 | 2026-01-01 | 加拿大商酵活英屬哥倫比亞有限公司 | 靶向dll3之三特異性抗體構築體及其使用方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3827019A1 (en) * | 2018-07-24 | 2021-06-02 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| EP3816185A1 (en) * | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
| TWI908779B (zh) * | 2020-03-17 | 2025-12-21 | 美商西雅圖免疫公司 | 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法 |
| WO2022016270A1 (en) * | 2020-07-20 | 2022-01-27 | Zymeworks Inc. | Fusion proteins comprising a ligand-receptor pair and a biologically functional protein |
-
2023
- 2023-01-26 IL IL314169A patent/IL314169A/en unknown
- 2023-01-26 JP JP2024544393A patent/JP2025504909A/ja active Pending
- 2023-01-26 AU AU2023212483A patent/AU2023212483A1/en active Pending
- 2023-01-26 CA CA3247443A patent/CA3247443A1/en active Pending
- 2023-01-26 EP EP23745768.4A patent/EP4469488A4/en active Pending
- 2023-01-26 KR KR1020247027803A patent/KR20240137058A/ko active Pending
- 2023-01-26 WO PCT/CA2023/050103 patent/WO2023141713A1/en not_active Ceased
-
2024
- 2024-07-24 MX MX2024009165A patent/MX2024009165A/es unknown
- 2024-07-24 US US18/783,028 patent/US20250019440A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4469488A1 (en) | 2024-12-04 |
| EP4469488A4 (en) | 2026-01-21 |
| JP2025504909A (ja) | 2025-02-19 |
| US20250019440A1 (en) | 2025-01-16 |
| KR20240137058A (ko) | 2024-09-19 |
| AU2023212483A1 (en) | 2024-09-05 |
| IL314169A (en) | 2024-09-01 |
| WO2023141713A1 (en) | 2023-08-03 |
| CA3247443A1 (en) | 2023-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024009165A (es) | Proteinas de fusion de ligador triespecifico del linfocito t inmunomodulador | |
| CY1124190T1 (el) | Anti-ctla4 μονοκλωνικο αντισωμα ή το θραυσμα δεσμευσης αντιγονου αυτου, φαρμακευτικη συνθεση και χρηση | |
| CY1120976T1 (el) | Δις ειδικα αντισωματα igg σαν παραγοντες ενεργοποιησης τ κυτταρων | |
| MX2025002974A (es) | Proteinas il-15/il-15ra de fusion a fc heterodimericas y usos de las mismas | |
| UY39118A (es) | ANTICUERPOS CONTRA SARS-Cov-2 (SARS2, COVID-19) | |
| BR112019014986A8 (pt) | Anticorpo que alveja bcma e uso do mesmo | |
| EP3923408C0 (en) | CONNECTION ASSEMBLY, BATTERY MODULE, BATTERY PACK AND DEVICE USING THE BATTERY MODULE AS A POWER SOURCE | |
| MX391028B (es) | Anticuerpos que se unen a cd39 y sus usos | |
| WO2009130618A3 (en) | Flagellin polypeptide vaccines | |
| MX2024005676A (es) | Receptores de celulas t que reconocen p53 mutado. | |
| UY36965A (es) | Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih | |
| MY206284A (en) | Anti-cd63 antibodies, conjugates, and uses thereof | |
| CY1118153T1 (el) | Αγωγη μικροβιακων μολυνσεων | |
| ECSP11010826A (es) | Citomegalovirus humano que neutraliza anticuerpos y su uso | |
| ES2694564T3 (es) | Polipéptidos de interleucina-2 mutantes | |
| BR112022006817A2 (pt) | Anticorpos direcionados a flt3 e uso dos mesmos | |
| UY30925A1 (es) | Proteinas de fusion de inmunoglobulina y metodos de elaboracion | |
| CY1116646T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
| CY1121795T1 (el) | Αντισωματα κατα toy cd52 | |
| BR112022010179A2 (pt) | Anticorpos anti-vírus da febre amarela, e métodos de sua geração e uso | |
| MX2019009121A (es) | Antcuerpos anti-kaag1 o fragmento de union al antigeno del mismo para el tratamiento de cancer de mama triple negativo. | |
| MX2023005179A (es) | Proteínas de unión que reconocen antígeno ha-1 y usos de las mismas. | |
| MX2017010359A (es) | Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc). | |
| BR112015017981A2 (pt) | anticorpo humano específico para metapneumovírus humano, ou fragmento de ligação de antígeno do mesmo, seu uso e composição farmacêutica o compreendendo, bem como ácido nucleico isolado, vetor de expressão recombinante e célula hospedeira | |
| CO2023013550A2 (es) | Polipéptido de unión a gucy2c y usos del mismo |